Now on Demand

Markers for COVID-19 Disease Progression: Comprehensive LC-MS characterization of the metabolome

Watch Now

Watch Professor Clare Mills from the University of Manchester discuss how LC/MS metabolomic techniques are used to profile serum from COVID-19 inpatients using our latest analytical workhorse, the Xevo G3 QTof.

Clare Mills Professor of Molecular Allergology University of Manchester

Professor Mills' research is focused on applying molecular science to understand, better diagnose and treat food allergies.

We will also discuss how core technology updates have improved workflows.

Learning Objectives

  • Discover how the new Xevo G3 QTof provides comprehensive characterization of analytes.
  • Develop understanding of LC/MS and its use in metabolomic and lipidomic studies.
  • Delve into the world of omics, identifying statistically relevant markers for disease and the impact on patients.

Who should attend

Scientists striving for improved instrument performance and ultimate confidence in their analytical workflows.

We look forward to seeing you there.

Bonus content: Robust and reliable MS platform to meet the challenges of extractables and leachables analysis.

Hear from Dr Andrew Feilden, Bicycle Therapeutics, on the application needs of Extractables and Leachables (E&L) analysis and learn how the latest Xevo G3 QTof Mass Spectrometer has been developed to ideally meet these requirements.

In addition, you will have the opportunity to see the Xevo G3 QTof system in operation in the European Demo Lab and hear an overview of the instrument from the product management team.

Watch on demand

HELLAMCO S.A.

Marketing Department

Newsletter

Sign up to Hellamco's Mailing List and check out our latest news.
HELLAMCO S.A. will process your personal data only for communication and updating purposes, will not distribute them on to third parties and will keep them in the database for 30 days. For more information regarding the processing of personal data and rights, please visit our relative privacy policy.